ATE329912T1 - (imidazol-1-yl-methyl)pyridazin als nmda- rezeptorblocker - Google Patents

(imidazol-1-yl-methyl)pyridazin als nmda- rezeptorblocker

Info

Publication number
ATE329912T1
ATE329912T1 AT03752750T AT03752750T ATE329912T1 AT E329912 T1 ATE329912 T1 AT E329912T1 AT 03752750 T AT03752750 T AT 03752750T AT 03752750 T AT03752750 T AT 03752750T AT E329912 T1 ATE329912 T1 AT E329912T1
Authority
AT
Austria
Prior art keywords
pyridazine
imidazole
methyl
nmda receptor
receptor blocker
Prior art date
Application number
AT03752750T
Other languages
English (en)
Inventor
Bernd Buettelmann
Neidhart Marie-Paule Heitz
Georg Jaeschke
Emmanuel Pinard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE329912T1 publication Critical patent/ATE329912T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03752750T 2002-05-16 2003-05-16 (imidazol-1-yl-methyl)pyridazin als nmda- rezeptorblocker ATE329912T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02010217 2002-05-16

Publications (1)

Publication Number Publication Date
ATE329912T1 true ATE329912T1 (de) 2006-07-15

Family

ID=29433072

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03752750T ATE329912T1 (de) 2002-05-16 2003-05-16 (imidazol-1-yl-methyl)pyridazin als nmda- rezeptorblocker

Country Status (30)

Country Link
US (1) US7005432B2 (de)
EP (1) EP1506190B1 (de)
JP (1) JP4267569B2 (de)
KR (1) KR100632868B1 (de)
CN (1) CN1312151C (de)
AR (1) AR040010A1 (de)
AT (1) ATE329912T1 (de)
AU (1) AU2003242542B2 (de)
BR (1) BR0311177A (de)
CA (1) CA2485926C (de)
CL (1) CL2004001251A1 (de)
CY (1) CY1105159T1 (de)
DE (1) DE60306152T2 (de)
DK (1) DK1506190T3 (de)
ES (1) ES2265581T3 (de)
HR (1) HRP20041060B1 (de)
IL (1) IL164922A (de)
MA (1) MA27117A1 (de)
ME (1) MEP76708A (de)
MX (1) MXPA04011253A (de)
NO (1) NO329605B1 (de)
NZ (1) NZ536310A (de)
PL (1) PL211340B1 (de)
PT (1) PT1506190E (de)
RS (1) RS51200B (de)
RU (1) RU2317294C2 (de)
SI (1) SI1506190T1 (de)
TN (1) TNSN04224A1 (de)
WO (1) WO2003097637A1 (de)
ZA (1) ZA200408789B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
EP1888706B1 (de) * 2005-05-03 2017-03-01 Merck Patent GmbH Organische elektrolumineszenzvorrichtung und in deren herstellung verwendete boronsäure- und borinsäure-derivate
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
JP5315710B2 (ja) * 2008-02-07 2013-10-16 セントラル硝子株式会社 １−ブロモ−３−フルオロ−５−ジフルオロメチルベンゼンの製造方法
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
MX2010009649A (es) * 2008-03-27 2010-12-17 Evotecv Neurosciences Gmbh Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda.
AU2010211050B2 (en) 2009-02-05 2016-05-12 Takeda Pharmaceutical Company Limited Pyridazinone compounds
EP2602255B1 (de) * 2010-08-04 2017-04-26 Takeda Pharmaceutical Company Limited Fusionierte heterozyklische ringverbindung
WO2012019106A2 (en) * 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2016025917A1 (en) * 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
JP7071917B2 (ja) 2015-12-09 2022-05-19 カデント セラピューティクス，インコーポレーテッド ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用
US10071988B2 (en) 2016-02-10 2018-09-11 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
CN108713016B (zh) 2016-02-18 2021-10-08 先正达参股股份有限公司 杀有害生物活性吡唑衍生物
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
AR115905A1 (es) 2018-08-03 2021-03-10 Cadent Therapeutics Inc 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda
CA3143103A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyridine carbamates and their use as glun2b receptor modulators
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
CN114008052A (zh) 2019-06-14 2022-02-01 詹森药业有限公司 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
MX2021015511A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
AU2020293642A1 (en) 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
TW202112774A (zh) 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
CN1131031C (zh) 1996-03-08 2003-12-17 弗·哈夫曼-拉罗切有限公司 作为nmda受体亚型阻断剂的4－苯基3，6－二氢－2h－吡啶基衍生物的应用
CA2220649C (en) 1996-12-03 2007-02-13 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
US6015824A (en) 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
ATE257827T1 (de) * 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
ATE274494T1 (de) 2000-04-20 2004-09-15 Hoffmann La Roche Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
US6432985B2 (en) 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
US7022882B2 (en) 2000-10-06 2006-04-04 The Regents Of The University Of California NMDA receptor channel blocker with neuroprotective activity
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
DE10120159A1 (de) 2001-04-25 2002-10-31 Merck Patent Gmbh NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives

Also Published As

Publication number Publication date
TNSN04224A1 (fr) 2007-03-12
CY1105159T1 (el) 2009-11-04
MXPA04011253A (es) 2005-01-25
IL164922A (en) 2012-01-31
HRP20041060B1 (en) 2012-11-30
RU2317294C2 (ru) 2008-02-20
CN1653062A (zh) 2005-08-10
DK1506190T3 (da) 2006-10-16
KR100632868B1 (ko) 2006-10-13
NZ536310A (en) 2007-08-31
CL2004001251A1 (es) 2005-04-22
NO329605B1 (no) 2010-11-22
IL164922A0 (en) 2005-12-18
AU2003242542B2 (en) 2008-10-16
RS98504A (sr) 2006-12-15
CA2485926A1 (en) 2003-11-27
EP1506190B1 (de) 2006-06-14
EP1506190A1 (de) 2005-02-16
HRP20041060A2 (en) 2005-06-30
PL374224A1 (en) 2005-10-03
US7005432B2 (en) 2006-02-28
MA27117A1 (fr) 2004-12-20
ES2265581T3 (es) 2007-02-16
HK1080845A1 (en) 2006-05-04
KR20040106558A (ko) 2004-12-17
JP4267569B2 (ja) 2009-05-27
US20030229096A1 (en) 2003-12-11
RU2004136979A (ru) 2005-07-10
MEP76708A (en) 2011-12-20
CA2485926C (en) 2009-11-24
JP2005532326A (ja) 2005-10-27
PT1506190E (pt) 2006-11-30
SI1506190T1 (sl) 2006-10-31
DE60306152T2 (de) 2007-04-26
AU2003242542A1 (en) 2003-12-02
ZA200408789B (en) 2005-12-28
DE60306152D1 (de) 2006-07-27
RS51200B (sr) 2010-12-31
NO20044666L (no) 2004-12-15
AR040010A1 (es) 2005-03-09
CN1312151C (zh) 2007-04-25
WO2003097637A1 (en) 2003-11-27
BR0311177A (pt) 2005-03-15
PL211340B1 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
DE60306152D1 (de) (imidazol-1-yl-methyl)pyridazin als nmda-rezeptorblocker
DE50304867D1 (en) Thiazolderivate als phosphodiesterase iv-inhibtoren
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
DE60320957D1 (en) Sulfonylderivate als histone-deacetylase-inhibitoren
DE60326549D1 (en) Aminocarbonylderivate als histone-deacetylase-inhibitoren
DE60321207D1 (en) Diaryläther als opioid-rezeptor antagonisten
PL379420A1 (pl) Pochodne blokerów receptora angiotensyny II
AU2003257094A1 (en) Substituted benzimidazole compounds
AU2003298273A1 (en) Chromatography system
DE60122495D1 (de) TRANS-N-i4-(4-HYDROXYPHENYL)CYCLOHEXYLö-3-PHENYLPROPIONAMID ALS SUBTYP-SELEKTIVER NMDA REZEPTOR ANTAGONIST
DE602004017438D1 (de) Biarylsubstituierte triazole als natriumkanalblocker
WO2005046122A8 (en) Computer network
AU2003257032A1 (en) Antibodies against c3a receptor
GB0304056D0 (en) Processor network
DE60306540D1 (en) Cyclopropylthienylcarbonsäureamide als fungizide
DE60319410D1 (en) Chinazolinderivate als src-tyrosinkinaseinhibitoren
AU2003226395A1 (en) Network processor architecture
AU2003295566A8 (en) Fault-tolerant multicasting network
AU2003245259A1 (en) Substituted imidazole derivatives: gabaa receptor ligands
AU2002255355A1 (en) Mechanism for fixing network apparatus
AU2003268770A1 (en) Sustained release preparation containing nk4
AU2003248251A1 (en) Exposure system
AU2002241284A1 (en) Network telephone system
TW536115U (en) Structure for fixing network accessories
AU2004903338A0 (en) User Interface for Workflow System

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1506190

Country of ref document: EP